GLP-1 peptide blind testing: verifying semaglutide, tirzepatide, and retatrutide

• Blind testing GLP-1 analogs means submitting an unlabeled sample of a putative semaglutide, tirzepatide, or retatrutide vial to an independent lab that does not know which molecule it is.
• The lab must identify the molecule from LC-HRMS alone — matching the intact mass within a few ppm of the theoretical monoisotopic mass (semaglutide ~4111.12 Da, tirzepatide ~4811.51 Da).
• Peptide mapping (tryptic digest + LC-MS) confirms the sequence and the lipid-linker position, which is where semaglutide, tirzepatide, and their common synthesis by-products diverge.
• Purity by RP-HPLC at 214 nm with the chromatogram attached, named side peaks where present, and integration thresholds stated.
• Cost: several hundred USD per sample for a full identity + purity + mapping panel; see the analog-specific pricing pages linked below.
• Interpretation: identity match + purity within method tolerance + content within stated range = pass. Any missing axis is not a partial pass — it is an incomplete verification.

The general blind-testing protocol applies to any peptide, but GLP-1 receptor agonists sit at the intersection of three properties that make identity a specific problem: they are large (39–40 residues), lipidated (a fatty-acid chain attached to a specific lysine via a γGlu-2xOEG linker on semaglutide, a different linker on tirzepatide), and they share most of their backbone with each other and with the native GLP-1 hormone.

A purity percentage on its own tells you almost nothing about a GLP-1 vial. A vial that is 99% pure of the wrong lipidated peptide — for example, semaglutide sold as tirzepatide, or an intermediate with the linker attached but no fatty-acid tail — is not a passing verification. Blind identity is the axis where GLP-1 testing is most often shortcut, and it is the axis a competent LC-HRMS + peptide-mapping panel is designed to close.

Chemistry references for the three main analogs: semaglutide, tirzepatide, and retatrutide. Each page lists the exact molecular formula, monoisotopic mass, and the analytical methods CertikLabs runs — the same numbers a blind report has to reproduce.

A GLP-1 blind submission follows the same shape as any blind test, with two GLP-1-specific practical notes.

1. Decant a representative aliquot into a fresh, unlabeled vial. For lyophilized material, transfer a small portion of powder under low humidity. For reconstituted solution, pipette an aliquot into a fresh vial.
2. Send at least 1 mg if the panel includes peptide mapping and amino-acid analysis. Identity-and-purity-only panels can run on less, but the digest for mapping consumes material and repeat injections need headroom.
3. Withhold the molecular identity, the vendor name, and any batch metadata. Specify only the assays you want: identity by LC-HRMS, purity by RP-HPLC, peptide mapping by trypsin digest + LC-MS, content by amino-acid analysis or validated UV.
4. Ship cold: GLP-1 analogs are stable as lyophilized powder at −20 °C but degrade quickly in reconstituted solution at room temperature. Overnight cold shipping with an ice pack is standard.

The split-sample variant is the strongest form: send aliquot A to a lab under its true label, aliquot B to a second lab blinded, and compare the two reports. For a buyer qualifying a new supplier, this is the audit worth paying for.

Every credible blind report on semaglutide, tirzepatide, or retatrutide has the same six features. Anything missing is a red flag; more than one absent is a sign the report is not measurement.

• Intact mass by LC-HRMS matched to the theoretical monoisotopic mass. Semaglutide 4111.12 Da, tirzepatide 4811.51 Da, retatrutide in the same class. Accuracy within ~5 ppm on a high-resolution instrument (Orbitrap or Q-TOF). The report should include the deconvoluted mass and the charge-state envelope.
• Peptide mapping by tryptic digest. The digest fragments are diagnostic for sequence, and the peptide carrying the lipidated lysine appears at a mass that is unique to the specific linker chemistry — semaglutide's γGlu-2xOEG-C18 vs. tirzepatide's differently-linked C20 fatty acid vs. retatrutide's fatty-acid tail. Mapping is what tells you the fatty-acid chain and the linker are actually present at the correct residue, not attached elsewhere or absent entirely.
• RP-HPLC purity with chromatogram attached. Detection at 214 nm on a C18 column with a TFA/acetonitrile gradient. Integration threshold and baseline visible. Named side peaks (deamidation products, oxidation, deletion sequences, unlipidated backbone) where present.
• Content by a quantitative method. Amino-acid analysis is the reference method for lipidated peptide content; a calibrated UV standard is acceptable if the calibration curve is included. A purity percentage without a content figure gives you no way to check the mg-per-vial claim.
• Method transparency. Instrument model, column, mobile phase, gradient, flow rate, injection volume, ionization mode, mass accuracy in ppm. Enough for another competent lab to reproduce the run.
• Sample chain of custody. When the vial arrived, in what condition, what it was labeled as on arrival. Closes the gap between "a sample was tested" and "this sample was tested."

A blind report on a GLP-1 analog gives you three numbers to reconcile against three references.

Identity. Compare the reported intact mass to the theoretical monoisotopic mass of the labeled analog. Semaglutide 4111.12 Da, tirzepatide 4811.51 Da. A mass error under about 5 ppm on a high-resolution instrument is a match; a difference of tens of Da is a different molecule. If the labeled identity does not match the observed mass, no purity or content figure can rescue the report — you have the wrong peptide.

Purity. The current market floor for a research-grade GLP-1 analog is ~98% purity by RP-HPLC at 214 nm. Anything meaningfully below 98% has quantified impurity content that matters for the milligram claim on the label. A purity number without the chromatogram is unverifiable; a purity of exactly 99.0% on every report the vendor has ever published is a template default, not an integration.

Content. The vial claim (e.g. "5 mg semaglutide") is a mass claim, not a purity claim. Content confirms that the labeled mass is actually there — a 5 mg vial at 98% purity should return roughly 4.9 mg of semaglutide by amino-acid analysis. Content that comes back well below the labeled mass indicates residual water, salts, TFA counter-ion, or short-fill; content that comes back at or above the label with high purity is a pass.

Failure patterns that appear on GLP-1 blind reports specifically — beyond the general failure modes:

• Identity reported as "GLP-1 analog" rather than the specific molecule. The instrument either did not resolve the intact mass or the analyst did not read the spectrum. Either way it is not a passing identity result.
• Peptide mapping absent from the report. On a lipidated 40-residue peptide, mapping is the assay that confirms the fatty acid is attached at the correct lysine. Skipping it leaves the biggest failure mode — a peptide with the correct backbone but the wrong or missing lipid linker — undetected.
• Semaglutide and tirzepatide swapped. The two masses differ by ~700 Da; any competent LC-HRMS resolves them. A report that returns the wrong analog is the strongest possible signal that the identity was taken from the label, not the spectrum.
• Unlipidated backbone reported as a passing result. The precursor peptide before fatty-acid conjugation has the correct amino-acid sequence and the correct number of residues; it will pass a sequence-only check. Only the intact-mass measurement plus the mapping of the lipidated lysine peptide catches this.
• Deamidation and oxidation products missing from the impurity list. GLP-1 analogs have asparagine and methionine residues that degrade during storage; a real chromatogram of an aged batch shows named peaks at +1 Da (deamidation) and +16 Da (Met oxidation). A report that never mentions them either has a very fresh sample or is not integrating anything.

A minimum-viable blind panel — identity by LC-HRMS plus purity by RP-HPLC — runs in the low-to-mid hundreds of USD per sample. Adding peptide mapping (trypsin digest + a second LC-MS run) and content by amino-acid analysis puts a full panel in the mid-to-high hundreds. Split-sample verification doubles that because two labs are running the work.

The current CertikLabs pricing for GLP-1 analog panels lives on the analog-specific pages: semaglutide testing cost, retatrutide testing cost. Tirzepatide pricing tracks the semaglutide panel closely because the analytical work is the same class of assay on a peptide of similar size.

Cost sensitivity is real, but the wrong place to save money on a GLP-1 verification is the identity axis. Purity without identity is a decimal place attached to nothing.

1. Decant a representative aliquot from the vial into a clean, unlabeled container. Keep cold in transit.
2. Submit through the standard intake without naming the vendor or stating the expected identity. Specify identity by LC-HRMS, purity by RP-HPLC, peptide mapping by trypsin digest, and content by amino-acid analysis or validated UV.
3. Receive a verification at a public URL. The report names the specific analog from the intact-mass spectrum, attaches the RP-HPLC chromatogram and the tryptic map, and reports content with method and tolerances stated.
4. Compare against the vendor's COA. Identity match, purity within method tolerance, and content within stated range together constitute a pass. Divergence on any axis is the information the test was designed to surface.

The same workflow supports a split-sample variant: a second aliquot from the same vial ships to a different lab under its true label, and the two reports become the comparison.